Medicover AB (publ) (MCVEF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medicover AB (publ) (MCVEF) trades at $27.25 with AI Score 47/100 (Grade C). Medicover AB (publ) is a leading healthcare and diagnostic services provider operating across Central and Eastern Europe. Market cap: $4.11B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for MCVEF: MCVEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MCVEF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MCVEF: the 1 perspectives are evenly split.
How is this calculated? →Medicover AB (publ) (MCVEF) Healthcare & Pipeline Overview
Medicover AB (publ) is a comprehensive healthcare and diagnostic services provider with a strong presence in Central and Eastern Europe, offering a diverse range of medical services through an extensive network of clinics and laboratories.
What Is the Investment Thesis for MCVEF?
Medicover AB (publ) presents a compelling investment thesis driven by its strong market presence and diverse service offerings. The company's market capitalization stands at $4.11 billion, with a P/E ratio of 36.3, indicating investor confidence in its growth potential. The healthcare sector is projected to grow significantly, particularly in Central and Eastern Europe, where rising incomes and an increasing demand for private healthcare services are evident. Medicover's strategic positioning, with 117 medical clinics and 25 hospitals, allows it to capitalize on this growth trend. Additionally, the company's gross margin of 23.3% and profit margin of 3.3% reflect operational efficiency, although there are risks associated with regulatory environments and currency fluctuations. As Medicover continues to expand its service offerings and geographical reach, it is well-positioned to leverage these growth catalysts while managing potential risks effectively.
Based on FMP financials and quantitative analysis
MCVEF Key Highlights
- Market capitalization of $4.11B reflects strong investor interest in healthcare services.
- P/E ratio of 36.3 indicates a premium valuation compared to industry peers.
- Profit margin of 3.3% demonstrates operational efficiency amid competitive pressures.
- Gross margin of 23.3% highlights the company's ability to maintain profitability in diverse markets.
- A workforce of 47,000 employees supports extensive healthcare operations across multiple countries.
Who Are MCVEF's Competitors?
MCVEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HCA HCA Healthcare, Inc. | $415.66 | +1.26% | $92.21B | 86 |
| UHS Universal Health Services, Inc. | $158.44 | +0.07% | $9.92B | 90 |
| MCK McKesson Corporation | $784.23 | -0.26% | $91.82B | 90 |
| LH Labcorp Holdings Inc. | $284.68 | -0.80% | $23.34B | 69 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCVEF's Key Strengths?
- Strong market presence in Central and Eastern Europe.
- Comprehensive range of healthcare and diagnostic services.
- Established relationships with corporate clients and public sector payers.
- Robust infrastructure with numerous clinics and laboratories.
What Are MCVEF's Weaknesses?
- Profit margin of 3.3% may limit financial flexibility.
- Exposure to diverse regulatory environments across operating countries.
- Dependence on private healthcare demand, which may fluctuate.
- Potential challenges in maintaining service quality amid rapid expansion.
What Could Drive MCVEF Stock Higher?
- Expansion into new geographic markets to capture growing healthcare demand.
- Development of advanced diagnostic services to enhance service offerings.
- Growth in fertility services to meet increasing patient demand.
- Launch of corporate wellness programs to tap into the corporate health market.
- Investment in telemedicine services to improve patient accessibility.
What Are the Key Risks for MCVEF?
- Rich valuation — a P/E of 36.3 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Regulatory changes that could impact healthcare operations.
- Currency fluctuations affecting financial performance across diverse markets.
- Intense competition from established healthcare providers in the region.
- Economic downturns that may reduce private healthcare spending.
What Are the Growth Opportunities for MCVEF?
- Expansion into New Geographic Markets: Medicover AB (publ) is strategically positioned to expand its operations into emerging markets within Central and Eastern Europe. The healthcare market in these regions is expected to grow at a CAGR of 8% over the next five years, driven by rising disposable incomes and an increasing demand for private healthcare services. By establishing new clinics and diagnostic centers, Medicover can capture a larger share of this growing market.
- Enhancement of Diagnostic Services: The global diagnostic services market is projected to reach $100 billion by 2027, growing at a CAGR of 6%. Medicover's extensive diagnostic capabilities, including advanced testing in areas like molecular biology and immunochemistry, provide a unique opportunity to expand its service offerings. By investing in cutting-edge technology and expanding its laboratory network, Medicover can enhance its competitive advantage and attract more clients.
- Growth in Fertility Services: The fertility services market is expected to grow significantly, with a projected value of $40 billion by 2026. Medicover operates 20 fertility clinics, positioning itself to benefit from this trend. By expanding its fertility services and offering innovative treatment options, the company can capture a larger share of this lucrative market segment.
- Corporate Wellness Programs: As businesses increasingly prioritize employee health, the demand for corporate wellness programs is on the rise. Medicover can leverage its extensive healthcare infrastructure to develop tailored wellness solutions for corporate clients, tapping into a growing market that is projected to reach $10 billion by 2025. This initiative would not only enhance client relationships but also drive revenue growth.
- Telemedicine Services: The telemedicine market is expected to grow to $185 billion by 2026, driven by the increasing adoption of digital health solutions. Medicover can expand its telemedicine offerings to provide remote consultations and follow-up care, enhancing accessibility for patients. This growth opportunity aligns with the global shift towards digital healthcare solutions and can significantly enhance Medicover's service delivery.
What Opportunities Does MCVEF Have?
- Expansion into emerging markets with growing healthcare demand.
- Increasing demand for telemedicine and digital health solutions.
- Growth potential in fertility services and corporate wellness programs.
- Enhancement of diagnostic services with advanced technology.
What Threats Does MCVEF Face?
- Regulatory changes impacting healthcare operations.
- Currency fluctuations affecting financial performance.
- Intense competition from established healthcare providers.
- Economic downturns impacting private healthcare spending.
What Are MCVEF's Competitive Advantages?
- Extensive network of clinics and laboratories across multiple countries.
- Diverse service offerings catering to various healthcare needs.
- Established brand reputation in the healthcare sector.
- Strong relationships with corporate clients and public sector payers.
- Innovative diagnostic capabilities and advanced medical technology.
What Does MCVEF Do?
Medicover AB (publ) was founded in 1995 and has since evolved into a prominent player in the healthcare sector, providing a wide array of healthcare and diagnostic services across multiple countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. The company operates through two main divisions: Healthcare Services and Diagnostic Services. The Healthcare Services division includes a robust network of medical clinics, hospitals, fertility clinics, dental clinics, and fitness centers, while the Diagnostic Services division offers a comprehensive range of tests, including allergy and autoimmune diagnostics, bacteriology, immunochemistry, and molecular biology. Medicover's extensive infrastructure comprises 97 clinical laboratories, 733 blood-drawing points, and 26 general clinics, ensuring a significant physical presence in its operating regions. The company serves a diverse clientele, including corporate clients, private individuals, direct patients, and public sector payers, positioning itself as a versatile provider in the healthcare landscape. With its headquarters in Stockholm, Sweden, Medicover continues to expand its footprint and adapt to the growing demand for private healthcare services in its core markets.
What Products and Services Does MCVEF Offer?
- Provide a wide range of healthcare services, including medical clinics and hospitals.
- Offer diagnostic services through a network of clinical laboratories and blood-drawing points.
- Cater to corporate clients, private individuals, and public sector payers.
- Operate fertility and dental clinics to meet diverse patient needs.
- Maintain fitness centers to promote overall health and wellness.
- Expand services across various countries in Central and Eastern Europe.
How Does MCVEF Make Money?
- Revenue generated from healthcare services provided in clinics and hospitals.
- Income from diagnostic services through laboratory testing and analysis.
- Fees from fertility treatments and dental services.
- Corporate contracts for employee health services and wellness programs.
- Membership and service fees from fitness center operations.
What Industry Does MCVEF Operate In?
The healthcare industry, particularly in the medical care facilities sector, is experiencing robust growth driven by increasing demand for quality healthcare services. The global healthcare market is expected to expand significantly, with a notable shift towards private healthcare solutions in Central and Eastern Europe. Medicover AB (publ) is well-positioned within this competitive landscape, offering a comprehensive range of services that cater to the evolving needs of patients and corporate clients. The company's extensive network of clinics and laboratories enhances its market presence, allowing it to compete effectively against other healthcare providers in the region.
Who Are MCVEF's Key Customers?
- Corporate clients seeking comprehensive employee health solutions.
- Private individuals requiring medical and diagnostic services.
- Public sector payers looking for healthcare partnerships.
- Patients seeking specialized services in fertility and dental care.
- Health-conscious individuals utilizing fitness center facilities.
How Medicover AB (publ) Is Valued
Medicover AB (publ) carries a market capitalization of $4.11B, placing it in the mid-cap category. Relative to its peer group, MCVEF's quantitative score of 47/100 is below the peer average of 80/100.
Company Profile
Medicover AB (publ) operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO John Paul Stubbington. MCVEF has traded publicly since 2019.
ROE 15%Key Financial Metrics
Return on equity for Medicover AB (publ) stands at 15.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.3%, showing how much profit it generates from its asset base. MCVEF trades at a trailing price-to-earnings ratio of 36.34, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.74 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Medicover AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.39 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Medicover AB (publ) revenue of about $2.62B for fiscal 2026, with EPS near $0.68. The estimate reflects 6 contributing analysts.
MCVEF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market presence in Central and Eastern Europe.
- Comprehensive range of healthcare and diagnostic services.
- Established relationships with corporate clients and public sector payers.
- Robust infrastructure with numerous clinics and laboratories.
Bear Case
- Profit margin of 3.3% may limit financial flexibility.
- Exposure to diverse regulatory environments across operating countries.
- Dependence on private healthcare demand, which may fluctuate.
- Potential challenges in maintaining service quality amid rapid expansion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MCVEF Latest News
-
European Growth Stocks With Strong Insider Ownership
Yahoo! Finance: MCVEF News · May 29, 2026
MCVEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCVEF.
Price Targets
Wall Street price target analysis for MCVEF.
MCVEF MoonshotScore
What does this score mean?
The MoonshotScore rates MCVEF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John Paul Stubbington
CEO
John Paul Stubbington has extensive experience in the healthcare sector, having held various leadership roles in both operational and strategic capacities. He holds a degree in Business Administration and has a proven track record of driving growth and operational efficiency in healthcare organizations. Prior to joining Medicover, he worked with several multinational healthcare firms, where he developed a deep understanding of the industry's dynamics.
Track Record: Under John Paul Stubbington's leadership, Medicover has expanded its network significantly, increasing the number of clinics and laboratories. He has also been instrumental in enhancing service offerings and improving operational efficiency, contributing to the company's overall growth and market positioning.
MCVEF OTC Market Information
The OTC Other tier includes companies that trade on the over-the-counter market but do not meet the requirements for higher tiers like OTCQX or OTCQB. This tier typically features companies with lower trading volumes and less stringent reporting standards compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity compared to stocks listed on major exchanges, leading to potential trading challenges.
- Less stringent reporting requirements may result in limited transparency for investors.
- Regulatory risks associated with operating in multiple countries with varying healthcare regulations.
- Currency risk due to operations in diverse markets, which can impact financial results.
- Verify the company's financial health through available reports.
- Assess the regulatory environment in key operating countries.
- Evaluate the competitive landscape and market positioning.
- Examine the company's growth strategy and expansion plans.
- Consider the impact of currency fluctuations on financial performance.
- Established brand presence in the healthcare sector since 1995.
- Extensive network of clinics and laboratories across multiple countries.
- Diverse service offerings catering to a wide range of healthcare needs.
Medicover AB (publ) Healthcare Stock: Key Questions Answered
What does Medicover AB (publ) do?
Medicover AB (publ) is a healthcare and diagnostic services provider operating in multiple countries. The company offers a wide range of services, including medical clinics, hospitals, diagnostic laboratories, fertility clinics, and fitness centers, catering to both private individuals and corporate clients.
What are the key growth opportunities for Medicover AB (publ)?
Medicover AB (publ) has several growth opportunities, including expansion into emerging markets, enhancement of diagnostic services, growth in fertility services, development of corporate wellness programs, and investment in telemedicine. These initiatives align with industry trends and the increasing demand for private healthcare services.
What are the main risks for Medicover AB (publ)?
Medicover AB (publ) faces several risks, including regulatory changes that could impact its operations, currency fluctuations affecting financial performance, and intense competition from other healthcare providers. Additionally, economic downturns may reduce private healthcare spending, which could impact revenue.
What are the key factors to evaluate for MCVEF?
Medicover AB (publ) (MCVEF) holds an AI score of 47/100 (low). P/E: 36.3x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does MCVEF data refresh on this page?
MCVEF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MCVEF's recent stock price performance?
Medicover AB (publ) (MCVEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence in Central and Eastern Europe. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MCVEF overvalued or undervalued right now?
Medicover AB (publ) (MCVEF) trades at 36.3x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MCVEF?
Before investing in Medicover AB (publ) (MCVEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company operates in diverse regulatory environments, which may introduce uncertainties in financial reporting.